Mitotane

From Wikipedia, the free encyclopedia

Mitotane
Systematic (IUPAC) name
1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)-ethyl]-benzene
Identifiers
CAS number 53-19-0
ATC code L01XX23
PubChem 4211
DrugBank APRD00494
Chemical data
Formula C14H10Cl4 
Mol. mass 320.04 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 6%
Metabolism  ?
Half life 18 to 159 days
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Mitotane is a medication used in the treatment of the rare disease adrenocortical carcinoma.

It has been produced by Bristol Myers Squibb SpA but it is marketed as an orphan drug due to the small number of patients in need of it. Its administration occurs in cases where the tumour cannot be surgically omitted.

Mitotane alternates steroides peripheral metabolism, represses directly the adrenal cortex and alternates cortisone metabolism. It is an isomere chemically to DDT.

Its trade name is Lysodren.

Mitotane is also used to treat pituitary-dependent Cushing's syndrome in canines. The medication is used in the controlled destruction of adrenal tissue, leading to a decrease in cortisol production. [1]

[edit] References

In other languages